Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

NCT05765084 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
15
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University Hospital, Antwerp

Collaborators